Highlights of This Issue 593

SPECIAL FEATURES

CCR Translations

595 New Treatments for Rhabdomyosarcoma: The Importance of Target Practice
Frederic G. Barr
See article p. 796

Molecular Pathways

598 Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma
Michele Carbone and Haining Yang

CCR Focus

606 A Millennium Goal for Cancer
Susan E. Bates

607 Overview of the AACR Clinical and Translational Cancer Research Think Tank Meeting
Kenneth C. Anderson and Raymond N. DuBois

612 Impact of Genomics on Personalized Cancer Medicine
Carlos L. Arteaga and José Baselga

619 Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics
David R. Parkinson, Bruce E. Johnson, and George W. Sledge

625 Genetically Modified Mouse Models for Biomarker Discovery and Preclinical Drug Testing
Raju Kucherlapati

631 Imaging: Strategies, Controversies, and Opportunities
Ronald Blasberg and David Piwnica-Worms

638 Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials
Donald A. Berry, Roy S. Herbst, and Eric H. Rubin

Review

645 Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence
David Páez, Melissa J. Labonte, Pierre Bohanes, Wu Zhang, Leonor Benhamin, Yan Ning, Takeru Watsutsuki, Fotios Loupakis, and Heinz-Josef Lenz

HUMAN CANCER BIOLOGY

654 Notch Signaling Promotes Growth and Invasion in Uveal Melanoma

666 Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features
Vassiliki Tzelepi, Jie Xin Zhang, Jing-Fang Lu, Brittany Kleb, Guanglin Wu, Xinhai Wan, Anh Hoang, Eleni Efthathiou, Kanishka Sircar, Nora M. Navone, Patricia Troncoso, Shoudan Liang, Christopher J. Logothetis, Sankar N. Maity, and Ana M. Aparicio
Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
Chung-Hsi Hsing, Hung-Chi Cheng, Yu-Hsiang Hsu, Chien-Hui Chan, Ching-Hua Yeh, Chien-Feng Li, and Ming-Shi Chang

Activation of β-Catenin Signaling in Androgen Receptor–Negative Prostate Cancer Cells
Xinhai Wan, Jie Liu, Jing-Fang Lu, Vassiliki Tzelepi, Jun Yang, Michael W. Starbuck, Lixia Diao, Jing Wang, Eleni Efstathiou, Elba S. Vazquez, Patricia Troncoso, Sankar N. Maity, and Nora M. Navone

MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer
Cristina Migliore, Valentina Martin, Vera P. Leoni, Angelo Restivo, Luigi Atzori, Annalisa Petrelli, Claudio Isella, Luigi Zorcolo, Ivana Sarotto, Giuseppe Casula, Paolo M. Cosmoiglio, Amedeo Columbano, and Silvia Giordano

Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways
Cristina Migliore, Valentina Martin, Vera P. Leoni, Angelo Restivo, Luigi Atzori, Annalisa Petrelli, Claudio Isella, Luigi Zorcolo, Ivana Sarotto, Giuseppe Casula, Paolo M. Cosmoiglio, Amedeo Columbano, and Silvia Giordano

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Jessica D. Sun, Qian Liu, Jingli Wang, Dharmendra Ahiwalia, Damien Ferraro, Yan Wang, Jean-Xin Duan, W. Steve Ammons, John G. Carr, Mark D. Matteucci, and Charles P. Hart

Omental Adipose Tissue–Derived Stromal Cells Promote Vascularization and Growth of Endometrial Tumors
Pharmacokinetically Stabilized Cystine Knot Peptides That Bind Alpha-v-Beta-6 Integrin with Single-Digit Nanomolar Affinities for Detection of Pancreatic Cancer

Tumor Infiltration by T Lymphocytes Expressing Chemokine Receptor 7 (CCR7) Is Predictive of Favorable Outcome in Patients with Advanced Colorectal Carcinoma
Pierpaolo Correale, Maria Saveria Rotundo, Cirino Botta, Maria Teresa Del Vecchio, Chiara Ginanneschi, Antonella Licchetta, Raffaele Conca, Serena Apollinari, Fabio De Luca, Pierfrancesco Tassone, and Pierosandro Tagliaferri

A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
Dung T. Le, Dirk G. Brockstedt, Ran Nir-Paz, Johannes Hampf, Shruti Mathur, John Nemunaitis, Daniel H. Sterman, Raifi Hassan, Eric Lutz, Bentley Moyer, Martin Giedlin, Jana-Lynn Louis, Elizabeth A. Sugar, Alice Pons, Andrea L. Cox, Jordana Levine, Aimee Luck Murphy, Peter Blei, Thomas W. Dubensky Jr, Joseph E. Eiden, Elizabeth M. Jaffee, and Daniel A. Laheru

Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
Adam D. Steg, Kerri S. Bevis, Ashwini A. Katre, Angela Ziebarth, Zachary C. Dobbins, Ronald D. Alvarez, Kui Zhang, Michael Conner, and Charles N. Landen

Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
Vincent A. de Weger, Annelies W. Turksma, Quirinus J.M. Voorham, Zelda Euler, Herman Beil, Alons J. van den Eertwegh, Elisabeth Bloemena, Herbert M. Pinedo, Jan B. Vermorken, Harm van Tinteren, Gerrit A. Meijer, and Erik Hooijberg

Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
Shuji Ogino, Kaori Shima, Jeffrey A. Meyerhardt, Nadine J. McCleary, Kimmie Ng, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Paul Schaefer, Renaud Whittom, Alexander Hantel, Al B. Benson III, Donna Spiegelman, Richard M. Goldberg, Monica M. Bertagnolli, and Charles S. Fuchs

Targeting Proteasomal Protein Degradation in Cancer—Letter
William K.K. Wu

Correction: Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4

LETTER TO THE EDITOR

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

CORRECTION
ABOUT THE COVER

A section of endometrial tumor xenografted in a mouse injected with Wi38 fibroblasts that fail to support tumor vascularization. Immunofluorescence analysis with antibodies against CD31 (green) and Ki67 (red) shows lack of CD31-positive vasculature and Ki67-positive proliferating cells exclusively in the peripheral tumor layer (bottom), whereas injection of omental adipose stromal cells increases tumor proliferation and vascularization. For details, see the article by Klopp and colleagues on page 771 of this issue.